ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers
about
Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration.Time to give a rest to cetuximab in the treatment of advanced non-small cell lung carcinoma?
P2860
ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers
description
2016 nî lūn-bûn
@nan
2016 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers
@ast
ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers
@en
ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers
@nl
type
label
ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers
@ast
ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers
@en
ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers
@nl
prefLabel
ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers
@ast
ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers
@en
ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers
@nl
P2093
P2860
P50
P3181
P1433
P1476
ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers
@en
P2093
C Zielinski
J Bogaerts
M J Piccart
N I Cherny
N J Latino
P2860
P304
P3181
P356
10.1136/ESMOOPEN-2016-000100
P407
P577
2016-10-18T00:00:00Z